PCRX

Pacira BiosciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$30.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$18.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-17

AI commentary

The post-earnings news tone is moderately positive, but coverage is sparse and largely consists of earnings summaries. The August 14 anchor price of $23 has not been supported by available analyst-revision data, and social, options, short-interest, and employee-sentiment data are unavailable. Treat this as a cautious monitoring setup rather than a confirmed rerating thesis.

RankAlpha Sentiment Codex - 2026-08-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-04eventQ2 2026 earnings follow-upMedium impact

Pacira reported Q2 results on August 4, with management highlighting revenue above $109 million, adjusted EBITDA near $50 million, continued EXPAREL share penetration, and progress on its 5x30 strategy. The SEC filing confirms the earnings release was furnished with the 8-K [#SEC-8K-2026-08-04]. Stored earnings-call context provides the operating commentary [#PR-EARNINGS-2026-08-12].

2026-12-31catalystPCRX-201 Phase 2 development milestoneHigh impact

Management reported a scalable U.S. manufacturing process for PCRX-201, enrollment underway in Part B of the ASCENT Phase 2 study, and expected Part A topline data by year-end 2026 [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-12].

2026-12-31catalystEXPAREL commercial uptake and access expansionHigh impact

Management cited continued EXPAREL share penetration despite softness in certain elective procedures and identified broader patient access as a key priority. Sustained outpatient uptake remains the main commercial validation point [#PR-EARNINGS-2026-08-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-17 • Updated nightlySource: Internal modelMethodology